International Biotechnology Trust (IBT)

Category Sector Equity Biotechnology

This investment trust can be held in an Investment ISA, SIPP and Investment Account

Some Investment Trusts include direct costs as part of their Ongoing charge, such as the annual management charge. For those that show Ongoing charges as 0% or a dash please review the investment literature for details on the charges that will apply. The Financial Conduct Authority will review this in 2025.

If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice.

Sell

980.00p

Buy

992.00p

arrow-up16.00p (+1.64%)

Discount/Premium

-6.00%

Estimated NAV

1,053.228p

Prices updated at 12 Dec 2025, 16:43 GMT

Prices minimum 15 mins delay

Prices in GBX

Investment objective

The Company’s investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies. The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with suitably experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.

FTSE All-Share

-0.48%

LSE

Important documents: Please ensure that you have read the Key Information Document/Technical Guide , Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and the fund information documents. These can be found within the Charges & documents section.

Director dealings

Date chevron-l-regular chevron-r-regular	Action
27 Aug 2025	Purchase
27 Aug 2025	Purchase
13 May 2025	Purchase
19 Feb 2025	Purchase
17 Dec 2024	Purchase

Director holdings

Name chevron-l-regular chevron-r-regular	Title	Amount (No. of shares)
Mr. Patrick Magee	Non-Executive Director, Senior Independent Director	11,500
Ms. Kate Cornish-Bowden	Non-Executive Director, Chairman	16,382
Ms. Gillian Elcock	Non-Executive Director	1,407
Ms. Alexa Henderson	Non-Executive Director	7,161
Professor Patrick H Maxwell CBE	Non-Executive Director	3,725

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Any ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar accepts no responsibility or liability whatsoever for the actions of third parties in this respect.